Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Update

Gossamer Bio, Inc. (NASDAQ:GOSS - Get Free Report) was the target of a large decline in short interest in the month of October. As of October 15th, there was short interest totalling 6,950,000 shares, a decline of 10.3% from the September 30th total of 7,750,000 shares. Based on an average daily trading volume, of 899,400 shares, the days-to-cover ratio is currently 7.7 days.

Wall Street Analysts Forecast Growth

Several research firms recently commented on GOSS. Wedbush reaffirmed an "outperform" rating and issued a $4.00 price objective on shares of Gossamer Bio in a report on Tuesday, August 13th. HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Gossamer Bio in a research report on Tuesday, September 17th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Gossamer Bio presently has an average rating of "Buy" and a consensus target price of $9.20.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of GOSS. US Bancorp DE acquired a new position in shares of Gossamer Bio in the 3rd quarter worth approximately $39,000. Sequoia Financial Advisors LLC lifted its stake in Gossamer Bio by 26.7% during the third quarter. Sequoia Financial Advisors LLC now owns 118,500 shares of the company's stock worth $117,000 after purchasing an additional 25,000 shares in the last quarter. Algert Global LLC purchased a new position in shares of Gossamer Bio during the second quarter worth $75,000. The Manufacturers Life Insurance Company grew its stake in shares of Gossamer Bio by 67.4% in the second quarter. The Manufacturers Life Insurance Company now owns 310,213 shares of the company's stock valued at $279,000 after buying an additional 124,913 shares in the last quarter. Finally, NEA Management Company LLC raised its holdings in shares of Gossamer Bio by 14.2% in the 2nd quarter. NEA Management Company LLC now owns 18,093,034 shares of the company's stock valued at $16,300,000 after buying an additional 2,255,025 shares during the period. Institutional investors and hedge funds own 81.23% of the company's stock.

Gossamer Bio Trading Down 2.0 %

Shares of NASDAQ GOSS traded down $0.02 during trading on Wednesday, hitting $0.90. 732,844 shares of the company were exchanged, compared to its average volume of 1,458,802. The company has a debt-to-equity ratio of 2.42, a quick ratio of 8.21 and a current ratio of 8.21. Gossamer Bio has a 12-month low of $0.46 and a 12-month high of $1.60. The company has a fifty day moving average price of $0.94 and a 200-day moving average price of $0.86. The firm has a market capitalization of $202.70 million, a PE ratio of -2.28 and a beta of 1.96.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last announced its quarterly earnings results on Monday, August 12th. The company reported $0.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.23 by ($0.01). The firm had revenue of $95.84 million for the quarter, compared to analyst estimates of $160.00 million. As a group, equities research analysts expect that Gossamer Bio will post -0.33 EPS for the current year.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.